In a revolutionary step, OpenAI is teaming with Retro Biosciences to push the boundaries of human lifespan. Revealed by MIT Technology Review, this joint effort aims to extend life by a decade leveraging AI’s breakthrough capabilities.
Backed by Sam Altman, Retro Biosciences has joined forces with OpenAI for roughly 12 months, focusing on the innovative objective of prolonging human life. Their key tool? The newly trained AI model named GPT-4b micro. This model focuses on reshaping proteins known as Yamanaka factors, converting human skin cells into youthful stem cells. This initiative, the company believes, paves the way for crafting human organs and offering ample supplies of replacement cells.
In contrast to Google’s Alphafold, a Nobel-awarded model that predicts protein shapes, GPT-4b micro is specifically designed for biological research, marking OpenAI’s debut in this area. Both firms have plans to unveil their research on the model and its results in the near future.
Original source: Read the full article on TechCrunch
